Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: Overall survival results from the randomized, double-blind, phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study
Professor Domenica Lorusso presented the overall survival results from the randomized, double-blind, phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study. Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer.
Presenter:
Domenica Lorusso
Oncology